WINNIPEG, Manitoba — February 12, 2026 — Leads & Copy — Kane Biotech Inc. (TSX-V:KNE) has announced the resumption of commercial activities in the United States and Canada for its revyve® Antimicrobial Wound Gel product line. The company has also appointed Sherida (Kay) Watkins Weaver and Patti Burke-Martin as Vice Presidents of Business Development.
Kane Biotech’s revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are cleared by the U.S. FDA 510(k) and approved by Health Canada.
In the U.S., Kane has signed non-exclusive distribution/sales agreements with Medstream Healthcare Solutions, LLC (Dorval, FL) and Patient Care Medical (Austin, TX), with initial shipments expected soon.
In Canada, Kane has resumed commercial activity by converting its distribution agreement with Best Buy Medical Canada to a non-exclusive arrangement, along with targeted sales and sampling initiatives.
Dr. Robert Huizinga, Interim CEO of Kane Biotech, stated that the company is executing on its commitment to reset Kane Biotech using a disciplined market approach. He added that the company will continue to generate scientific credibility, clinical validation, and commercial infrastructure.
Sherida (Kay) Watkins Weaver has been appointed Vice President of Business Development, United States. She brings over 20 years of experience in wound care commercialization, including leadership roles at Omeza and Relevate Health. She has led market access, reimbursement, and adoption strategies across health systems, long-term care, and home health markets.
Patti Burke-Martin has been appointed Vice President of Business Development, Canada. She has held senior roles at EO2 Concepts, Coloplast, and ConvaTec and has a proven track record in building high-performing teams and driving adoption of advanced wound care technologies across Canada.
Dr. Huizinga added that Kay and Patti bring deep expertise and trusted relationships in their respective markets. He stated that their leadership will be instrumental as the company expands its distribution network and supports the growing adoption of revyve.
Kane Biotech is commercializing and developing wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms contribute to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria.
To learn more, visit revyvegel.com or revyvegel.ca.
Source: Kane Biotech Inc.
